CJC-1295 & GHRP-2 UK: What Are These Compounds?

CJC-1295

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that drives pituitary GH secretion. It consists of the first 29 amino acids of GHRH with strategic substitutions to increase protease resistance and extend half-life.

Two forms exist in research: CJC-1295 No DAC (without Drug Affinity Complex) and CJC-1295 with DAC. The No DAC form has a half-life of approximately 30 minutes — producing discrete GH pulses. The DAC form extends this to 6–8 days via albumin binding — producing sustained GH elevation.

GHRP-2

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide ghrelin mimetic. It stimulates GH secretion by binding the ghrelin receptor (GHSR-1a) on pituitary somatotrophs — a mechanism entirely distinct from GHRH receptor activation. Among the GHRP family (GHRP-2, GHRP-6, Ipamorelin, Hexarelin), GHRP-2 demonstrates the highest GH secretion potency in preclinical models.

CJC-1295 GHRP-2 Blend UK: Dual Mechanism of Action

The scientific rationale for the CJC-1295 GHRP-2 blend UK lies in its dual receptor activation. The two compounds act on separate G-protein coupled receptor systems, each independently driving GH release — and critically, acting synergistically when combined.

The cAMP pathway (CJC-1295) and the calcium/IP3 pathway (GHRP-2) converge at the level of GH exocytosis. Co-activation of both pathways amplifies the GH pulse to a significantly greater magnitude than either pathway alone — this is the mechanistic basis for the synergy observed in CJC-1295 GHRP-2 blend UK research protocols.

Additionally, GHRP-2’s ghrelin receptor activity suppresses somatostatin (SRIF) release from the hypothalamus. Somatostatin is the primary inhibitory brake on GH secretion. GHRP-2 disinhibits this brake while CJC-1295 simultaneously stimulates the accelerator — producing maximal GH pulse amplitude. For further reading on GHRH-GHRP synergy mechanisms, see Penalva et al., Journal of Clinical Endocrinology (1998).

CJC-1295 GHRP-2 Blend UK: Why the Blend Outperforms Individual Compounds

Preclinical and clinical research consistently demonstrates that co-administration of GHRH analogues + GHRP compounds produces GH responses 2–10x greater than either compound administered alone.

For researchers studying GH axis physiology, IGF-1 downstream signalling, or somatotropic function, the blend provides the most physiologically impactful stimulation model available without pharmacological GH administration.

CJC-1295 No DAC vs With DAC: Which for Blend Research?

This is one of the most common questions among CJC-1295 GHRP-2 blend UK researchers. The choice has significant implications for protocol design.

For CJC-1295 GHRP-2 blend UK research, CJC-1295 No DAC is the correct form. Its 30-minute half-life matches GHRP-2’s kinetics, producing synchronised dual-pathway activation and the characteristic large pulsatile GH release that mirrors endogenous GH physiology. CJC-1295 with DAC is better suited to standalone sustained GH elevation protocols.

CJC-1295 GHRP-2 Blend UK: Preclinical Research Evidence

GH Pulse Studies

Rodent studies using simultaneous GHRH analogue + GHRP administration consistently demonstrate synergistic GH pulse responses. The Penalva et al. work demonstrated that combined GHRH + GHRP-2 produced GH responses approximately 5-fold greater than GHRH alone in human volunteers — establishing the synergy as a clinically relevant phenomenon.

IGF-1 Downstream Effects

Following pulsatile GH release from combined CJC-1295 GHRP-2 blend UK protocols, hepatic IGF-1 synthesis is markedly elevated. Rodent models show significant increases in circulating IGF-1 with preserved pulsatile GH kinetics — an important distinction from exogenous GH administration, which produces tonic elevation.

Body Composition Research Models

Combined GHRH + GHRP-2 protocols in rodent models have been used to study GH-dependent lipolysis (via HSL activation in adipocytes) and GH-dependent protein synthesis (via IGF-1 receptor activation in muscle). These models provide a GH axis stimulation framework without direct GH administration.

CJC-1295 GHRP-2 UK Sourcing Standards

Both CJC-1295 and GHRP-2 require standard peptide purity verification. Key criteria:

• HPLC ≥98% for each peptide component — independently verified
• Mass spectrometry — CJC-1295 MW: 3647.3 Da; GHRP-2 MW: 817.9 Da
• Batch-specific CoA with lot number for each vial
• Independent third-party testing — not supplier self-certification

For pre-blended CJC-1295 GHRP-2 blend UK formats, additionally require documentation of the blend ratio and combined purity verification. UK-Peptides does not conduct independent third-party testing per their own public statements. Arma Peptides supplies all CJC-1295 and GHRP-2 formats with full independent CoA documentation.

CJC-1295 GHRP-2 UK Supplier Comparison

Competitor data based on publicly available information as of May 2026. Prices approximate.

Arma Peptides: CJC-1295 GHRP-2 Blend UK Research Range

Arma Peptides supplies the complete CJC-1295 GHRP-2 blend UK research range — including the pre-blended format and all individual components — with independent CoA verification on every batch.

For researchers building broader GH axis protocols, Arma also supplies:

• CJC-1295 with DAC 10MG — sustained GH elevation research
• Ipamorelin 5MG — selective GH secretagogue, GHRP-2 alternative with cleaner receptor profile
• HGH 100IU — direct GH for comparative axis research
• IGF-1 LR3 1MG — downstream IGF-1 pathway research

CJC-1295 GHRP-2 Blend UK Research Protocol Checklist

Frequently Asked Questions — CJC-1295 GHRP-2 Blend UK

All products supplied by Arma Peptides are for laboratory research purposes only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified researchers only.